Condition: Primary Ovarian Leiomyosarcoma · Sponsor: Azienda USL Reggio Emilia - IRCCS
This observational study aims to gather comprehensive data on primary ovarian leiomyosarcoma (POLMS). This extremely rare malignancy accounts for less than 3% of primary ovarian malignancies and has an incidence of only 1% among ovarian cancers. This national, retrospective and prospective multicenter study will collect and analyze historical cases of POLMS with remote diagnoses accessed through clinical case reviews and newly identified cases. The study aims to expand a previously identified series of 113 cases described in the literature, uncovering patterns in diagnosis, treatment, and outcomes and ultimately establishing evidence-based guidelines for the optimal management of this rare and aggressive cancer.
This description comes directly from the study's public registry record.
Vincenzo Dario Mandato, MD · +39 0522 295467 · vincenzodario.mandato@ausl.re.it
Always discuss trial participation with your own doctor first.
| AOU Policlinico di Modena | Modena, Italy, Italy | Recruiting |
| Azienda Ospedaliero Universitaria di Parma - S.C. Ostetricia e Ginecologia | Parma, PR, Italy | Recruiting |
| Azienda USL IRCCS di Reggio Emilia | Reggio Emilia, RE, Italy | Recruiting |
| Malzoni - Avellino | Avellino, Italy | Recruiting |
| Azienda Ospedaliero Universitaria Policlinico "G.Rodolico - San Marco" - Catania | Catania, Italy | Recruiting |
| IRCCS Ospedale San Raffaele | Milan, Italy | Recruiting |
| Fondazione Irccs San Gerardo Dei Tintori | Monza, Italy | Recruiting |
| IRCCS Istituto Nazionale Tumori Fondazione Pascale | Naples, Italy | Recruiting |
| Università degli Studi di Napoli Federico II | Naples, Italy | Recruiting |
| Ospedale "Sacro Cuore" | Verona, Italy | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06749600